Tagged with ess

Taiwan Taiwan is entering a pivotal phase in its healthcare evolution, and Roche’s leaders in Taiwan outline how the convergence of global expertise, advanced diagnostics and innovative therapeutics can accelerate that shift. Diana Liu and Sophia Chao describe an ecosystem that is eager to adopt prevention, early detection and personalised care,…

Global Pharma in 2026 will be defined by unpredictability. Executives are already being pushed by shifting policy, commercial, and scientific forces into making fast and tough strategic choices, with more to come throughout the year, as regular contributor Brendan Shaw lays out in his annual look-ahead.   Senior executives in the…

Taiwan Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing from Neurology Head for Taiwan and Hong Kong to regional leadership across Southeast Asia, she now steers both affiliates through…

Taiwan Lian-Yu Chen, Director General of Taiwan’s National Health Insurance Administration, combines expertise in clinical psychiatry, public health, and governmental leadership. A PhD graduate of Johns Hopkins Bloomberg School of Public Health, she specialised in service utilisation and barriers to care. Dr Chen has driven Taiwan’s digital infrastructure and data governance…

Hong Kong Amy Ho, General Manager of Roche Pharma Hong Kong, returns to the city with a unique blend of diagnostics and pharmaceutical experience at a moment when the healthcare system is redefining its future. Drawing on years of regional leadership, she offers a clear view of how Hong Kong can strengthen…

Taiwan Under Dave Huang’s leadership, Ferring Taiwan has evolved from organisational recovery to sustained performance and regional relevance. The discussion that follows examines how disciplined focus, early engagement with innovation, and deep collaboration with the healthcare ecosystem have reshaped the affiliate’s role, positioning Taiwan as a reference market while anchoring strategy…

LatAm Fernando Zarate, Vice President of Bausch Health’s Latin American operations, outlines the company’s strategic positioning across the region. With 35 years in the industry and nearly two decades at Bausch Health, he today oversees one of the top 15 companies in the LatAm market. Zarate sets out a vision to…

Taiwan Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She discusses Gilead’s strategic evolution from virology specialist to diversified oncology player, the complexities of navigating diverse Asian healthcare systems, and…

France Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With two years at LEEM and one year on the EFPIA Board, Peyraut is operating under unprecedented geopolitical pressures reshaping pharmaceutical…

Mexico Ricardo Amtmann, President of Sanfer Group, discusses the company’s evolution from a licensing-dependent operation into Latin America’s most vertically integrated pharmaceutical enterprise. With nearly 14,000 employees across the region, Sanfer has transformed through strategic acquisitions, manufacturing investments, and a principled approach to market expansion. Amtmann articulates his vision for Mexico’s…

Brazil Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology transfer agreements is bolstering local manufacturing capabilities and helping these companies scale the value chain. Multinationals – with the right…

Taiwan Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech, she returned to Taiwan a decade ago and brought two companies to IPO on the Taipei stock exchange.  She joined…